Literature DB >> 34950305

An Uncommon Dilemma: Cardiac Resynchronization Therapy in Patients with Persistent Left Superior Vena Cava Draining into the Coronary Sinus.

Omar R Kahaly1, Muhammad R Afzal1, Toshimasa Okabe1, Mahmoud Houmsse1.   

Abstract

Entities:  

Year:  2020        PMID： 34950305      PMCID： PMC8691343          DOI： 10.4022/jafib.2339

Source DB:  PubMed          Journal:  J Atr Fibrillation        ISSN： 1941-6911


× No keyword cloud information.
  6 in total

1.  Coronary venoplasty-assisted implantation of cardiac resynchronization device in a patient with persistent left superior vena cava.

Authors:  Charles Cagin; Gregory W Barsness; Paul A Friedman; Yong-Mei Cha
Journal:  Heart Rhythm       Date:  2009-06-06       Impact factor: 6.343

2.  Implantable cardioverter defibrillator lead implantation in patients with a persistent left superior vena cava--feasibility, chances, and limitations: representative cases in adults.

Authors:  M Guenther; S Kolschmann; T P Rauwolf; M Christoph; V Sandfort; R H Strasser; C Wunderlich
Journal:  Europace       Date:  2012-09-19       Impact factor: 5.214

3.  Left superior vena cava persistence in patients undergoing pacemaker or cardioverter-defibrillator implantation: a 10-year experience.

Authors:  M Biffi; G Boriani; L Frabetti; G Bronzetti; A Branzi
Journal:  Chest       Date:  2001-07       Impact factor: 9.410

Review 4.  Right Ventricular Versus Biventricular Pacing for Heart Failure and Atrioventricular Block.

Authors:  Hiroko Beck; Anne B Curtis
Journal:  Curr Heart Fail Rep       Date:  2016-10

5.  Interventional approach to CRT in a patient with drainage of the superior vena cava into the coronary sinus.

Authors:  Seth Joseph Worley; Douglas Charles Gohn; Robert Ward Pulliam
Journal:  Pacing Clin Electrophysiol       Date:  2008-04       Impact factor: 1.976

6.  Hybrid right-left cardiac resynchronization therapy defibrillator implantation in persistent left superior vena cava.

Authors:  Matteo Anselmino; Maria Cristina Marocco; Claudia Amellone; Riccardo Massa
Journal:  Europace       Date:  2008-12-26       Impact factor: 5.214
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.